Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates
~ Lantern is expanding RADR®’s product roadmap to enhance the development of novel and effective Antibody Drug Conjugates (ADCs) for the targeted delivery of potent anti-cancer small molecules to cancer cells.
~ RADR®’s AI and ML drug development modules have the potential to assist in advancing ADC drug candidates from the discovery phase to first-in-human clinical trials in approximately 2 years or less.
~ Lantern anticipates this expansion will significantly add to RADR®’s 25+ billion oncology focused data points and library of over 200+ algorithms.
~ The global ADC market is over $4.0 billion and is projected to reach $14.0 billion by 2027.
DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.